FSD PHARMA INC.
199 Bay Street, Suite 4000
Toronto, Ontario M5L 1A9
December 29, 2023
Via EDGAR
Division of Corporation Finance Office of Trade and Services U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 |
| Re: | FSD Pharma Inc. Registration Statement on Form F-3 (File No. 333-276264) Acceleration Request |
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended (the “Act”), FSD Pharma Inc. (the “Company”), hereby requests that the effectiveness of the above-referenced Registration Statement on Form F-3 (the “Registration Statement”) be accelerated to, and that the Registration Statement become effective at 4:00 p.m. (Eastern Time) on January 4, 2024, or as soon thereafter as practicable. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
The Company hereby authorizes Daniel D. Nauth, an attorney with our outside legal counsel, Nauth LPC, to orally modify or withdraw this request for acceleration.
Please contact Daniel D. Nauth of Nauth LPC at (416) 477-6031 with any questions with respect to this request.
| Sincerely, | ||
|
|
|
| FSD Pharma Inc. |
|
| /s/Zeeshan Saeed | ||
|
|
|
| Zeeshan Saeed Chief Executive Officer | |
|
|
|
| cc: Daniel D. Nauth, Nauth LPC |
